Children with metastatic retinoblastoma are considered to have a poor prognosis after conventional chemotherapy. We used high-dose chemotherapy (HDC) with peripheral hematopoietic stem cell transplantation in such patients in an attempt to improve their survival. Four patients with bone marrow metastases and one child with extraorbital disease were treated with HDC after achieving complete remission by enucleation and conventional chemotherapy. The child with extraorbital tumor was the only one to receive local irradiation. The conditioning regimen included thiotepa (900 mg/m 2 ), etoposide (40 mg/kg) and carboplatin (1.5 g/m 2 ) in four patients, and BCNU (300 mg/m 2 ), cyclophosphamide (6.8 g/m 2 ) and etoposide (1.6 g/m 2 ) in one child. Hematologic recovery occurred without delay in all patients. The main toxicities were diarrhea, mucositis and infectious complications. No toxic deaths or any major late toxicities were observed. The child treated with the BCNU regimen developed a meningeal relapse 10 months after HDC, which was partially resected and treated with conventional chemotherapy, but not with radiotherapy. He is in complete remission (CR) 105 months off treatment. The other patients are in CCR for 107, 57, 9 and 8 months after HDC. HDC with thiotepa, etoposide and carboplatin may represent a curative option for children with extrabulbar or disseminated retinoblastoma responsive to chemotherapy. It may control occult CNS disease. The necessity to irradiate these children and the curative potential of this strategy for patients with bulky CNS disease remain to be determined.
) in four patients, and BCNU (300 mg/m 2 ), cyclophosphamide (6.8 g/m 2 ) and etoposide (1.6 g/m 2 ) in one child. Hematologic recovery occurred without delay in all patients. The main toxicities were diarrhea, mucositis and infectious complications. No toxic deaths or any major late toxicities were observed. The child treated with the BCNU regimen developed a meningeal relapse 10 months after HDC, which was partially resected and treated with conventional chemotherapy, but not with radiotherapy. He is in complete remission (CR) 105 months off treatment. The other patients are in CCR for 107, 57, 9 and 8 months after HDC. HDC with thiotepa, etoposide and carboplatin may represent a curative option for children with extrabulbar or disseminated retinoblastoma responsive to chemotherapy. It may control occult CNS disease. The necessity to irradiate these children and the curative potential of this strategy for patients with bulky CNS disease remain to be determined. Bone Marrow Transplantation (2003) 31, 281-284. doi:10.1038/sj.bmt.1703832 Keywords: retinoblastoma; high-dose chemotherapy; hematopoietic stem cell transplantation Retinoblastoma is the most common primary tumor of the eye in children. 1 Its cure rate reaches 95% (10-year survival probability of 687 patients, German Childhood Cancer Registry, 2). In most cases, the disease is diagnosed early and local treatment is instituted promptly. RB remains a high-risk malignancy, however, under certain circumstances, such as involvement of the cut end of the optic nerve, 3, 4 extrascleral spread into the orbita 5, 6 or lymphatic, or hematogenous dissemination. 7 Central nervous system disease has a particularly bad prognosis. 1, 8 Attempts to control or even cure disseminated retinoblastoma have followed the strategies used in neuroblastoma, the other and more frequent disseminated neuroectodermal malignancy of childhood. 9, 10 Responses of metastatic retinoblastoma have been shown to respond to cisplatin-etoposide and cyclophosphamide-doxorubicin, 5, 11 and to etoposide and carboplatin. 12 Since it has been very difficult to convert such responses into cures, 7 the dose-response concept has been advocated and tried for retinoblastoma as for neuroblastoma, germ-cell tumors or brain tumors. Unlike these diseases, the paucity of patients has prevented a larger prospective trial to date.
We report our experience with four children who suffered from bone marrow metastases of retinoblastoma, responded to conventional chemotherapy and received high-dose consolidation chemotherapy (HDC). A fifth child received the same treatment for extraocular orbital disease.
Patients and methods
Five children (two girls) received HDC for retinoblastoma in Germany from 1992 until 2001. In all of them, a unilateral retinoblastoma had primarily been diagnosed at the age of 20, 31, 34, 64 and 110 months. In three children, histopathologic risk factors were seen: tumor at the cut end of the optic nerve (patient 2), invasion of the choroid (patients 2, 3) and microscopic extrascleral disease (patient 5). There was no evidence of CNS disease in any of them at the time of first diagnosis. The affected eye was enucleated in each case. Patient 5 had documented extrascleral disease, and received additional external irradiation of 48 Gy and adjuvant chemotherapy according to the Essen Retinoblastoma Protocol (cyclophosphamide, etoposide, carboplatin and vincristine, cf. Bornfeld et al 13 ); no local radiotherapy was given to the other patients. The characteristics of these patients are summarized in Table 1 .
Four children (patients 1-4) developed metastatic bone marrow involvement 5, 6, 9 and 11 months after eye surgery. Bone scan was negative in all patients except patient 3, who had lesions in the left temporal bone and in the third thoracic vertebra. At this time again, no CNS disease was detectable in them by imaging or CSF cytology. They received multiagent chemotherapy, two children according to the Neuroblastoma Protocol NB 90, Protocol of the German Society of Pediatric Oncology/Hematology, (including cisplatin, etoposide, vindesine, vincristine, DTIC, ifosfamide and doxorubicin), and two children according to the Essen Retinoblastoma Protocol. 13 In all five children, peripheral blood stem cells (PBSC) were mobilized using filgrastim 5 mg/kg/day subcutaneously after one of the chemotherapy blocks, in patient 2 after treatment with 4 g/m 2 of cyclophosphamide. The PBSC were cryopreserved; in patients 3 and 4, a CD34+ selection was performed beforehand. Informed consent was obtained from the parents of each patient.
All patients were in complete remission (CR) at the time of HDC (cf. Table 2 ).
During the period of HDC, supportive care was given according to local standards, including barrier nursing, selective oral decontamination, oral antifungal treatment, pneumocystis carinii prophylaxis with trimethoprim/sulfamethoxazole before day 0 and after hematopoietic recovery, and parenteral nutritional support as necessary. As consolidation therapy, patient 1 received BCNU 300 mg/ m Table 3 ). PBSC containing 1.7-21.0 Â 10 6 CD34+ cells/ kg were thawed and infused on day 0. Concomitantly, treatment with filgrastim at a dose of 5 mg/kg/day was initiated and continued until stable neutrophil engraftment was reached.
Results
Prompt reconstitution of bone marrow occured in all patients. Neutrophil counts of 40.5/nl were reached on day 10 (median; range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Rising unsupported platelet numbers of 450/nl were noted by day 22 (median; range 12-51). The main toxicities included diarrhea and severe mucositis (WHO grade 3 and 4 in patients 2-5) requiring opiate analgesics in all patients, and nausea and vomiting. All children developed fever and received antibiotics, but septicemia could not be documented in any of them. Transient elevation of liver enzymes was noted in three patients. Further acute or late toxicities have not been observed to date.
All patients are alive and well 8-119 months after HDC (cf. Table 2 ). A right frontal meningeal relapse occured in patient 1 10 months after HDC. After partial metastasectomy and conventional chemotherapy according to the Essen Retinoblastoma Protocol 13 plus multiple intrathecal of methotrexate injections, this boy has been in second CR for 105 months (no radiotherapy).
Discussion
For many years, retinoblastoma confined to the eye has been a curable disease with local therapy such as enucleation, external beam irradiation, brachytherapy, cryotherapy or laser coagulation. 1 In contrast, systemic disease is difficult to cure, although it usually responds to chemotherapy. [5] [6] [7] As in other malignancies of similar prognosis, high dose intensification of chemotherapy has been tried for retinoblastoma. Two case reports of patients with bone marrow metastases who received HDC in complete remission and survived in continuous remission 13 and 17 months thereafter gave a first hint to the possiblility of cure in metastatic retinoblastoma. 14, 15 Later, the group of the Institut Curie in Paris published their results after treating 25 high-risk patients with retinoblastoma, with HDC consisting of carboplatin, etoposide and cyclophosphamide (CARBOPEC), followed by autologous bone marrow rescue. Among eight children with bone marrow and bone metastases, five survived between 11 and 70 months disease free, while three patients relapsed in the CNS and died. 8 Among all 25 patients, a total of seven suffered from recurrence after this HDC, six of these seven within the CNS. The authors conclude that CNS disease cannot be cured with the CARBOPEC regimen. 8 CNS involvement is well known to confer a very poor prognosis. Aggressive chemotherapy regimens including CCNU, intrathecal therapy and cranial irradiation have resulted in considerable toxicity, but have not yielded an applicable number of cures. 10 We therefore included drugs : alternating combinations of two of the three agents cyclophosphamide (40 mg/kg), etoposide (15 mg/kg) and carboplatin (10 mg/kg) with 0.05 mg/kg of vincristin added to each block. A total of six blocks were given within 5-6 months.
High-dose chemotherapy with autologous stem cell B Kremens et al into our HDC regimens, which are active in intracerebral tumors. After having treated patient 1 with BCNU, CY and ETO, and after noting the French experience with CARBOPEC, which inadequately controlled CNS disease, 8 we decided to modify this regimen and replaced the alkylating agent cyclophosphamide with thiotepa. Thiotepa metabolized in vivo to its major active metabolite tepa, is a polyfunctional alkylating agent that has been used for many years in the treatment of ovarian and breast cancer. In children, its maximal tolerated bolus dose is 65 mg/m 2 , with reversible myelosuppression being the dose-limiting toxicity. 16, 17 It penetrates well into the brain, as demonstrated by similar drug levels in cerebrospinal fluid and in serum after i.v. bolus use. 16 At conventional dose levels, mucosal, renal, hepatic, neurologic or cutaneous toxicity has been absent. Therefore, thiotepa has been considered for HDC. It has been studied at doses of 750-900 mg 2 as single drug in children with solid tumors, [18] [19] [20] in combination with other drugs as consolidation for solid tumors 21, 22 and in children with myeloid malignancies. 23 Owing to its good penetration into the CNS, HDC studies in brain tumors have included thiotepa. [24] [25] [26] [27] The investigators observed considerable, but manageable, toxicity with high-dose thiotepa. A response of retinoblastoma to conventional dose thiotepa is documented in one case. 16 For all these reasons, we decided to include thiotepa into the HDC regimen for children with high-risk RB and have treated four children with this approach. Toxicity was considerable, but manageable. These four patients, three of whom had been treated because of previous bone marrow relapse, are alive and in CR for 124, 69, 24 and 14 months after the initial diagnosis of the disease and 107, 57, 9 and 8 months after high-dose treatment (patient 3 has been described in a case report, 28 ). No CNS relapse has been observed to date. Clearly, however, the follow-up of the last two patients is still too short to consider them no longer at risk. It should be emphasized that none of the three children with bone marrow relapse has ever had any radiotherapy. Meanwhile, Dunkel and colleagues from New York have reported four patients who were treated according to the same rationale with these three drugs, carboplatin, etoposide and thiotepa, in an HDC setting. After HDC, they all received radiotherapy of 19.5-40 Gy to sites of previous bulky disease, which included either the orbit or the base of skull. All four were reported as having survived disease-free for 46-80 months from diagnosis of the metastatic disease. 29 Considering this experience and ours together, it can be cautiously concluded that HDC with carboplatin, etoposide and thiotepa produces long-term continuous remissions in patients with previous bone marrow and/or bone involvement by retinoblastoma and may even be able to control minimal residual disease in the CNS. The question of whether additional radiotherapy to the orbit or to sites High-dose chemotherapy with autologous stem cell B Kremens et al of parameningeal bone lesions is needed to prevent CNS relapse in patients with histologic involvement of the cut end of the optic nerve is still open. The high risk of second cancers in familial retinoblastoma would be reason enough to omit irradiation in as many of these patients as possible. In Namouni's and our series of patients, bone metastases as evidenced by bone scan were found in a total of nine patients. Five of them survived without radiotherapy (patients 14-17 Namouni et al; 8 patient 3, this report). In only two of these five did, the bone metastases involve the skull (patient 17, Namouni et al; 8 patient 3, this report). Three patients of Namouni et al had skull lesions and received radiotherapy; in two of them, a CNS relapse occured nonetheless. 8 We support Namouni's hypothesis that metastases in parameningeal bones can spread into the cerebrospinal fluid. This phenomenon can also be observed in children with neuroblastoma and skull metastases. Since retinoblastoma within the CNS is still virtually incurable, this risk should be minimized by all means including irradiation. Patients with bone metastases not involving skull and spine, however, might be spared radiotherapy with the intention of decreasing the risk of secondary cancers.
Clearly, more patients with longer follow-up are needed to confirm these results and to answer the open questions. The small number of patients anticipated requires the cooperation of several national groups.
